Severe cardiac amyloidosis may represent a critical risk factor for fatal left ventricular rupture during transapical TAVI.
Answers are grounded in this paper and cite their sources.
Cardiac amyloidosis may raise fatal LV rupture risk after transapical TAVI; leaves open need for pre-procedural screening.
Transcatheter aortic valve implantation via transarterial or transapical access is an alternative therapy to treat high-risk patients with severe symptomatic aortic stenosis. Despite growing experience, procedural complications may still occur. We herein report an 86-year-old female patient with fatal left ventricular rupture after transapical transcatheter aortic valve implantation with an Edwards Sapien prosthesis due to severe cardiac amyloidosis.
No takes yet. Share an insight, caveat, or question.
Monticelli et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: